Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment

Non-interventional Study Describing Direct Costs Related to Anticoagulation Treatment in Patients With Nonvalvular Atrial Fibrillation (NVAF) in Secondary Stroke Prevention Prescribed Apixaban or Warfarin Treatment

To describe the direct costs related to warfarin/apixaban treatment

To describe the direct costs related to warfarin/apixaban treatment during the first 6 months of the secondary stroke prevention in NVAF patients.

Inclusion Criteria:

• Diagnosis of non-valvular atrial fibrillation (NVAF);
• New initiation of anticoagulation therapy (apixaban or warfarin) due to the ischemic event (stroke/TIA) meaning patients previously not anticoagulated due to diagnosis of NVAF;
• Indication to anticoagulation therapy as a secondary stroke prevention within 7 to 30 days after the stroke/TIA event;
• Apixaban arm: genetically determined higher sensitivity to warfarin;
• Patients whose status allowed oral treatment with apixaban/warfarin;
• Age ≥ 18;
• Access to patient´s records of the first 6 months of the warfarin/apixaban treatment.

Exclusion Criteria:

• Diagnosis of valvular disease;
• Treatment with other anticoagulants in previous 6 months due to other the NVAF indication;
• Treatment or prophylaxis of deep vein thrombosis or pulmonary embolism;
• Contraindications according SmPC of Eliquis